Study of the Effects of PRALIA 60 mg Subcutaneous Injection Syringe on the Physical Functions, etc. of Rheumatoid Arthritis Patients

Study of the Effects of the Long-term Use of Denosumab - PRALIA 60 mg Subcutaneous Injection Syringe - on the Physical Functions, etc. of Rheumatoid Arthritis Patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031210189

Enrollment

960

Registered

2021-07-09

Start date

2013-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Initial examination, diagnosis of rheumatoid arthritis, receipt of a prescription for a DMARD (including biologics) during the enrollment period at the Kyoto University Hospital Rheumatic Disease Center

Exclusion criteria

Exclusion criteria: History of a bone or joint surgical procedure, receipt of a prescription for a RANKL inhibitor prior to the day of the initial examination at the Kyoto University Hospital Rheumatic Disease Center

Design outcomes

Primary

Measure	Time frame
-HAQ(Health Assessment Questionnaire)score	—

Contacts

Public ContactContact for GPSP

Daiichi Sankyo Co.,Ltd.

contact_gpsp@daiichisankyo.co.jp+81-3-6225-1059

Outcome results